15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $3.7B | $314M | 81.8% | 13.5% | $465M | — | $1.7B |
| 2024 | $2.2B | -$278M | 86.4% | -7.9% | -$43M | — | $966M |
| 2023 | $1.8B | -$440M | 85.3% | -15.4% | $42M | — | $813M |
| 2022 | $1.0B | -$1.1B | 86.5% | -75.7% | -$613M | — | $866M |
| 2021 | $844M | -$853M | 86.4% | -83.9% | -$718M | $676M | $820M |
| 2020 | $493M | -$858M | 84.9% | -168.1% | -$685M | $191M | $497M |
| 2019 | $220M | -$886M | 88.6% | -427.5% | -$419M | — | $547M |
| 2018 | $75M | -$761M | 97.6% | -1087.6% | -$690M | — | $420M |
| 2017 | $90M | -$491M | 100.0% | -556.2% | -$487M | — | $645M |
| 2016 | $47M | -$410M | 0.0% | -900.3% | -$372M | — | $194M |
| 2015 | — | -$290M | — | — | — | — | $181M |
| 2014 | — | -$360M | — | — | — | — | $75M |
| 2013 | — | -$89M | — | — | -$73M | — | $53M |
| 2012 | — | -$106M | — | — | -$124M | — | $51M |
| 2011 | — | -$58M | — | — | -$88M | — | $70M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Dec '25 | $1.1B | $186M | 75.6% | 12.0% | $140M | — | $1.7B |
| Sep '25 | $1.2B | $251M | 84.2% | 29.5% | $313M | — | $1.5B |
| Jun '25 | $774M | -$66M | 81.6% | -2.1% | $139M | — | $1.1B |
| Mar '25 | $594M | -$57M | 88.2% | 3.0% | -$127M | — | $1.0B |
| Dec '24 | $593M | -$84M | 82.7% | -17.7% | -$104M | — | $966M |
| Sep '24 | $501M | -$112M | 83.6% | -15.4% | $40M | — | $1.1B |
| Jun '24 | $660M | -$17M | 89.8% | 7.4% | $116M | — | $968M |
| Mar '24 | $494M | -$66M | 89.0% | -8.8% | -$94M | — | $682M |
| Dec '23 | $440M | -$138M | 83.6% | -26.5% | -$45M | — | $813M |
| Sep '23 | $751M | $148M | 89.4% | 28.5% | $342M | — | $1.0B |
| Jun '23 | $319M | -$276M | 76.4% | -72.1% | -$75M | — | $658M |
| Mar '23 | $319M | -$174M | 87.0% | -46.9% | -$180M | — | $672M |
| Dec '22 | $335M | -$207M | 86.2% | -56.3% | -$154M | — | $866M |
| Sep '22 | $264M | -$406M | 86.2% | -97.6% | -$132M | — | $1.1B |
| Jun '22 | $225M | -$277M | 84.9% | -85.3% | -$139M | $678M | $576M |
| Mar '22 | $213M | -$240M | 89.0% | -68.8% | -$189M | $677M | $534M |
| Dec '21 | — | -$258M | — | — | -$172M | $676M | $820M |
| Sep '21 | — | -$205M | — | — | -$160M | $434M | $1.1B |
| Jun '21 | $221M | -$190M | 86.3% | -66.3% | -$133M | $433M | $746M |
| Mar '21 | $178M | -$200M | 87.0% | -104.9% | -$253M | $192M | $380M |
How the market has priced ALNY against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Alnylam Pharmaceuticals's revenue has grown 49.8% per year. These are computed facts, not advice.
As of FY2025, Alnylam Pharmaceuticals reported — of total debt against $1.7B of cash; operating income covered interest expense 2.0×.
In FY2025, gross margin was 81.8%, operating margin 13.5%, and net margin 8.4%.
As of Jun '26, Alnylam Pharmaceuticals traded at a price-to-earnings ratio of about 124.0× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.